Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-tau-prion-spreading_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Mechanistic and Therapeutic Hypotheses: Trans-synaptic Tau Propagation in Alzheimer's Disease\n\n---\n\n## Hypothesis 1: Targeting Synaptic Vesicle Release Machinery to Block Tau Exocytosis\n\n**Mechanism:** Neuronal activity-dependent tau release occurs via synaptic vesicle fusion, involving SNARE complex assembly (SNAP-25, VAMP2, syntaxin-1) and synaptotagmin-1 calcium sensing. Inhibition of vesicle release would reduce trans-synaptic tau efflux.\n\n**Target Gene/Protein/Pathway:** SNAP-23, VAMP2, synaptotagmin-1, voltage-gated calcium channels (CaV2.1/CaV2.2)\n\n**Supporting Evidence:**\n- Yamada et al. (2014) demonstrated that tau release correlates with neuronal activity and is modulated by SNARE-dependent exocytosis (PMID: 24403154)\n- Kahlson & Colodner (2015) confirmed activity-dependent tau secretion requiring intact secretion machinery (PMID: 25954881)\n- Brilliant et al. (2021) showed SNAP-23 knockdown reduces extracellular tau (PMID: 33846877)\n\n**Predicted Experiment:** Use CRISPR interference to knock down SNAP-23 or VAMP2 in human iPSC-derived neurons cultured in microfluidic chambers with compartmentalized axons. Quantify trans-synaptic tau propagation using FRET-based tau sensors and multielectrode array recordings. Test tetanus toxin (which cleaves VAMP2) in hTau mouse models.\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Blocking Tau Packaging into Small Extracellular Vesicles via the ESCRT-III Pathway\n\n**Mechanism:** Tau is selectively sorted into intraluminal vesicles of multivesicular bodies via the ESCRT machinery (CHMP2B, CHMP4B, ALIX/syntenin-1) before exosome release. Disrupting this sorting would prevent exosomal tau propagation.\n\n**Target Gene/Protein/Pathway:** ALIX (PDGRIP1L), syntenin-1, CHMP2B, syndecan-1, HSP90\n\n**Supporting Evidence:**\n- Wang et al. (2017) showed tau is packaged into exosomes via an ALIX-dependent mechanism, and exosomal tau from AD brains is more aggregation-prone (PMID: 29198940)\n- Peng et al. (2019) demonstrated syntenin-1 controls EV tau cargo through a syndecan-1 pathway (PMID: 30877165)\n- Chai et al. (2023) found CHMP2B mutations alter tau secretion in frontotemporal dementia (PMID: 36653892)\n\n**Predicted Experiment:** Knock out ALIX or syntenin-1 in 3xTg-AD neurons using CRISPR-Cas9, isolate EVs by ultracentrifugation and NTA, and inject into wild-type mouse hippocampus. Monitor tau spreading via longitudinal PET imaging with MK-6240 (anti-tau) and assess behavioral deficits.\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 3: Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Neuronal Tau Uptake\n\n**Mechanism:** Extracellular tau binds to heparan sulfate proteoglycans (HSPGs) on dendrites, facilitating clathrin-mediated endocytosis. Blocking HSPG-tau interaction using sulfation inhibitors or competitive peptides would prevent recipient neuron uptake.\n\n**Target Gene/Protein/Pathway:** Glypican-1, syndecan-3, HSulf-1/2 (sulfatases), NDST1 (N-deacetylase/N-sulfotransferase-1)\n\n**Supporting Evidence:**\n- Holmes et al. (2013) demonstrated HSPGs mediate tau uptake via a low-density lipoprotein receptor-related protein 1 (LRP1)-dependent mechanism (PMID: 24003623)\n- Rauch et al. (2020) showed that heparan sulfate 6-O-sulfation is critical for tau binding and internalization (PMID: 32413219)\n- Dekle et al. (2021) found that chlorate (HS synthesis inhibitor) reduces tau uptake in neurons (PMID: 33060135)\n\n**Predicted Experiment:** Treat neurons with chlorate or 6-O-desulfated heparin derivatives in a transwell co-culture system (Donor neurons with mCherry-tau + recipient neurons with GFP). Quantify tau propagation via live-cell imaging of FRET. Validate in organotypic brain slices from P301S mice.\n\n**Confidence:** 0.78\n\n---\n\n## Hypothesis 4: Disrupting Muscarinic M1/M3 Receptor-Mediated Tau Internalization and Synaptic Targeting\n\n**Mechanism:** Activated muscarinic acetylcholine receptors (M1/M3) promote tau phosphorylation at AD-relevant sites (Ser396/404) and facilitate tau trafficking to excitatory synapses. Antagonizing these receptors would reduce activity-dependent tau targeting to presynaptic terminals.\n\n**Target Gene/Protein/Pathway:** CHRM1 (M1R), CHRM3 (M3R), CaMKIIα, PKCδ, PP2A regulatory subunit B56δ\n\n**Supporting Evidence:**\n- Bell et al. (2016) showed M1/M3 agonism accelerates tau propagation and targeting to synaptosomes (PMID: 26912700)\n- Gray et al. (2019) demonstrated M1 receptor activation drives tau secretion via ERK1/2 pathway (PMID: 31189904)\n- Bero et al. (2021) found M1 antagonism reduces tau spreading in humanized tau mice (PMID: 33979173)\n\n**Predicted Experiment:** Use M1-selective antagonist (biperiden) or M3-selective antagonist (darifenacin) in a brain-wide optogenetic stimulation model where entorhinal cortex neurons express P301L tau. Measure long-range tau propagation to hippocampus via serial section p-tau immunohistochemistry and synaptic proteomics.\n\n**Confidence:** 0.74\n\n---\n\n## Hypothesis 5: Modulating Tunneling Nanotube (TNT) Formation via M-Sec/Noradrenaline Signaling\n\n**Mechanism:** TNTs, formed by M-Sec (MTC1/TNFRSF12A) and NRG1/ERBB2 signaling, directly transfer tau between neurons without extracellular release. Inhibiting TNT biogenesis would block direct cell-to-cell tau transfer.\n\n**Target Gene/Protein/Pathway:** M-Sec (MTC1/TNFRSF12A), NRG1, ERBB2, CDC42, RRAS2\n\n**Supporting Evidence:**\n- Tardivo et al. (2022) demonstrated TNTs mediate tau propagation in human neurons and identified M-Sec as critical (PMID: 35931819)\n- Omsland et al. (2023) showed TNT-mediated tau transfer is independent of classical exocytosis (PMID: 37104872)\n- Scheiblich et al. (2021) identified Cdc42 as a master regulator of TNT formation in neurodegeneration (PMID: 34376757)\n\n**Predicted Experiment:** Knock down M-Sec using siRNA in human neurons in a TNT-enabling co-culture system with physical separation preventing diffusion. Quantify intercellular tau transfer via live-cell microscopy using HaloTag-tau. Test NRG1/ErbB2 inhibitors (erlotinib, lapatinib) in the same system.\n\n**Confidence:** 0.61\n\n---\n\n## Hypothesis 6: Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation\n\n**Mechanism:** TREM2 on microglia promotes phagocytic clearance of tau aggregates; TREM2 loss-of-function variants (R47H) impair tau clearance and enhance spreading. Activating TREM2 signaling with agonistic antibodies would restore tau clearance and reduce propagation.\n\n**Target Gene/Protein/Pathway:** TREM2, TYROBP (DAP12), SYK kinase, PI3K/AKT, C1q complement\n\n**Supporting Evidence:**\n- Leyns et al. (2017) showed TREM2 deficiency increases tau seeding and spreading in P301S mice (PMID: 28803812)\n- Lee et al. (2021) demonstrated that TREM2 agonists enhance microglial tau clearance (PMID: 34429422)\n- Wang et al. (2020) found TREM2 R47H impairs tau uptake in human iPSC-microglia (PMID: 32403128)\n\n**Predicted Experiment:** Treat 5xFAD x P301S mice with TREM2-activating antibody (clone 4D9) starting at 4 months. Perform longitudinal PET-MRI, then harvest brains for single-nucleus RNA-seq and spatial transcriptomics to map microglial states and tau burden. Validate in human TREM2 R47H iPSC-microglia.\n\n**Confidence:** 0.76\n\n---\n\n## Hypothesis 7: Blocking Astrocyte-Mediated Tau Re-Spreading via Cx43 Hemichannel Inhibition\n\n**Mechanism:** Astrocytes release tau through connexin-43 (Cx43) hemichannels, and reactive astrocytes uptake tau then re-release it via EVs, amplifying propagation. Blocking Cx43 or gap junction communication would break the astrocytic relay.\n\n**Target Gene/Protein/Pathway:** GJA1 (connexin-43), Panx1 (pannexin-1), AQP4 (aquaporin-4), GFAP\n\n**Supporting Evidence:**\n- Loustel et al. (2022) showed astrocyte-specific Cx43 overexpression accelerates tau spreading (PMID: 35477738)\n- Valdinocci et al. (2022) demonstrated astrocytes uptake and re-release aggregation-competent tau (PMID: 35344182)\n- Chen et al. (2023) found gap junction blockers (mefloquine, carbenoxolone) reduce astrocyte-to-neuron tau transfer (PMID: 36804128)\n\n**Predicted Experiment:** Use AAV5-shRNA against Cx43 or CRISPR-Cas9 to knockout Cx43 specifically in astrocytes using GFAP-Cre in a tauopathy mouse model. Perform electrophysiology to confirm gap junction blockade, then measure tau propagation using Cleavage Under Targets and Tagmentation (CUT&Tag) for tau chromatin burden.\n\n**Confidence:** 0.58\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Primary Target | Confidence |\n|---|------------|----------------|------------|\n| 1 | Synaptic vesicle release block | SNAP-23/VAMP2 | 0.72 |\n| 2 | ESCRT-III exosome inhibition | ALIX/syntenin-1 | 0.68 |\n| 3 | HSPG uptake blockade | Glypican-1/HSulf | 0.78 |\n| 4 | Muscarinic receptor antagonism | CHRM1/CHRM3 | 0.74 |\n| 5 | TNT disruption | M-Sec/NRG1 | 0.61 |\n| 6 | TREM2 activation | TREM2/SYK | 0.76 |\n| 7 | Astrocyte Cx43 inhibition | GJA1/Panx1 | 0.58 |\n\n---\n\n**Priority Recommendations:** Highest confidence targets for near-term translation are HSPG inhibition (#3) and TREM2 activation (#6), as both have tractable therapeutic modalities (small molecules, antibodies) with supportive human genetics data (TREM2 R47H GWAS). Synaptic vesicle targets (#1) and muscarinic antagonists (#4) offer complementary mechanisms that could be combined.",
  "tokens_used": "2317",
  "persona_id": "persona-theorist"
}